DRAK1 Polyclonal Antibody, FITC Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-6770R-FITC-100uL |
| Product Name | DRAK1 Polyclonal Antibody, FITC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Chicken, Rabbit |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human DRAK1/STK17A |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9263 |
| Subcellular location | Nucleus |
| Synonyms | DAP kinase-related apoptosis-inducing protein kinase 1; death-associated protein kinase-related 1; EC 2.7.11.1; Serine / threonine kinase 17a death associated protein kinase related 1; Serine/threonine kinase 17a; Serine/threonine protein kinase 17a; STK17 A; STK17A; ST17A_HUMAN. |
| Background | DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1) is a novel member of the ser/thr protein kinase family, which mediate apoptosis through their catalytic activities. The full-length cDNA encodes a deduced 414-amino acid protein with a molecular mass of 46.56 kD. DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. DRAK1 messenger RNA appears to be ubiquitously expressed in human tissues. Overexpression of DRAK1 induces apoptosis. It has been shown in vitro that DRAK1 is capable of autophosphorylation and of phosphorylating the myosin light chain as an exogenous substrate, and that the noncatalytic C terminus is crucial for full kinase activity. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is DRAK1 Polyclonal Antibody, FITC Conjugated (bs-6770R-FITC) validated for, and at what dilution?
bs-6770R-FITC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-6770R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise DRAK1 Polyclonal Antibody, FITC Conjugated (bs-6770R-FITC)?
KLH conjugated synthetic peptide derived from human DRAK1/STK17A
What are the excitation and emission wavelengths of the FITC conjugate (bs-6770R-FITC)?
FITC on bs-6770R-FITC: excitation / emission 494nm/518nm.